Advertisement

Guillain-Barré-Syndrom und chronische entzündliche demyelinisierende Polyradikuloneuritis

  • R. Gold
  • W. Müllges
  • K. V. Toyka

Zusammenfassung

Nach dem fast völligen Verschwinden der Poliomyelitis ist das Guillain-Bar-ré-Syndrom (GBS) die häufigste Ursache akuter peripherer Lähmungen in der westlichen Welt geworden. Die jährliche Inzidenz liegt zwischen 1 und 2 Fällen/100 000 Einwohner mit leichter Bevorzugung des männlichen Geschlechts. Initial wird häufig über periphere sensible Reizerscheinungen geklagt. Dann treten innerhalb kurzer Zeit motorische Ausfälle auf. Diese sind zunächst an den Extremitäten distal akzentuiert, können sich aber wegen der Mitbeteiligung der Spinalwurzeln auch rasch auf proximale Muskeln ausdehnen:

Rasch aufsteigende Lähmungen sind typisch.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Weiterführende Literatur

  1. Buchwald B, Weishaupt A, Toyka KV, Dudel J (1998) Pre-and postsynaptic blockade of neu-romuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur J Neurosci 10:281–290.CrossRefPubMedGoogle Scholar
  2. Buchwald B, Dudel J, Zielasek J, Weishaupt A, Schweiger S, Toyka KV (1998) Neuromuscu-lar blockade by IgG antibodies from patients with Guillain-Barré syndrome. Ann Neurol 44:913–922.CrossRefPubMedGoogle Scholar
  3. Dutch Guillain-Barré Study Group (1994) Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 35:749–752.CrossRefGoogle Scholar
  4. Dyck PJ, Litchy WJ, Kratz KM et al. (1994) A plasma exchange vs. immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838–845.CrossRefPubMedGoogle Scholar
  5. Enders U, Karch H, Toyka KV et al. (1993) The spectrum of immune responses to campylo-bacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmu-nological disorders. Ann Neurol 34:136–144.CrossRefPubMedGoogle Scholar
  6. Flachenecker P, Wermuth P, Hartung HP, Reiners K (1997) Quantitative assessment of cardiovascular autonomic function in Guillain-Barré syndrome. Ann Neurol 42:171–179.CrossRefPubMedGoogle Scholar
  7. French Cooperative Group on Plasma Exchange in Guillain-Barré-Syndrome (1987) Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 22:753–761.CrossRefGoogle Scholar
  8. French Cooperative Group on Plasma Exchange in Guillain-Barré-Syndrome (1997) Appropriate number of plasma exchanges in Guillain-Barré syndrome [see comments]. Ann Neurol 41:298–306.CrossRefGoogle Scholar
  9. Gold R, Härtung HP (1993) Therapie von Immunneuropathien. Akt Neurol 20:147–160.CrossRefGoogle Scholar
  10. Guillain-Barré-Syndrome Steroid Trial Group (1993) Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 341:586–590.Google Scholar
  11. Hadden RDM, Cornblath DR, Hughes RAC et al. (1998) Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 44:780–788.CrossRefPubMedGoogle Scholar
  12. Härtung HP, Pollard JD, Harvey GK, Toyka KV (1995) Immunopathogenesis and treatment of the Guillain-Barré syndrome — part I and part II. Muscle Nerve 18:137–164.CrossRefPubMedGoogle Scholar
  13. Ho TW, Hsieh ST, Nachamkin I et al. (1997) Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection [see comments]. Neurology 48:717–724.CrossRefPubMedGoogle Scholar
  14. Hughes RAC (1990) Guillain-Barré syndrome. Springer, London Berlin Heidelberg.CrossRefGoogle Scholar
  15. Hughes RAC, Swan AV, Cornblath DR et al. (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 349:225–230.CrossRefGoogle Scholar
  16. Jacobs BC, Endtz H, van der Meché FGA et al. (1995) Serum anti-GQ1b IgG antibodies recognize surface epitopes on campylobacter jejuni from patients with Miller Fisher syndrome. Ann Neurol 37:260–264.CrossRefPubMedGoogle Scholar
  17. Kiefer R, Kieseier BC, Brück W, Härtung H-P, Toyka KV (1998) Macrophage differentiation antigens in acute and chronic autoimmune polyneuropathies. Brain 121:469–479.CrossRefPubMedGoogle Scholar
  18. Li CY, Xue P, Tian WQ, Liu RC, Yang C (1996) Experimental campylobacter jejuni infection in the chicken: An animal model of axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 61:279–284.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Ropper AH (1992) The Guillain-Barré syndrome. N Engl J Med 326:1130–1136.CrossRefPubMedGoogle Scholar
  20. Schmidt B, Toyka KV, Kiefer R, Full J, Härtung HP, Pollard J (1996) Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 19:474–487.CrossRefPubMedGoogle Scholar
  21. Stängel M, Härtung HP, Marx P, Gold R (1997) Side effects of high-dose intravenous immu-noglobulins. Clin Neuropharmacol 20:385–393.CrossRefPubMedGoogle Scholar
  22. Stängel M, Toyka KV, Gold R (1998) Mechanisms of high dose intravenous immunoglobu-lins in demyelinating diseases. Arch Neurol (in press).Google Scholar
  23. Toyka KV, Härtung HP (1996) Chronic inflammatory polyneuritis and related neuropathies. Curr Opin Neurol 9:240–250.CrossRefPubMedGoogle Scholar
  24. Van der Meche FGA, Schmitz PIM, and the Dutch Guillain-Barré Study Group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 326:1123–1129.CrossRefPubMedGoogle Scholar
  25. Weiß H, Ravtan V, Müllges W, Toyka KV (1999) Psychotic symptoms and emotional distress in patients suffering from acute Guillain-Barré syndrome (in Vorbereitung).Google Scholar
  26. Winer JB, Hughes RAC, Osmond C (1988) A prospective study of acute idiopathic neuropathy. I: Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 51:605–612.CrossRefPubMedPubMedCentralGoogle Scholar
  27. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K et al. (1993) A bacterium lipopo-lysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 178:1771–1775.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • R. Gold
  • W. Müllges
  • K. V. Toyka

There are no affiliations available

Personalised recommendations